The article discusses information about erdafitinib, which is the first targeted therapy that the U.S. Food and Drug Administration approved for treatment of metastatic bladder cancer. Topics covered include the recommended starting dose for erdafitinib, central serous retinopathy/retinal pigment epithelial detachment caused by erdafitinib, and its reproductive risk of embryo-fetal toxicity.